Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.41 |
| ▸ | PPARA | Q07869 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4605138 | 0.81 | L3MBTL1 (0.54) | AKR1C3FFAR1PPARAMAPTL3MBTL1 | |
| SCHEMBL4603923 | 0.79 | AKR1C3 (0.46) | AKR1C3FFAR1PPARAMEN1POLB | |
| SCHEMBL1826193 | 0.79 | MRGPRX4 (0.61) | AKR1C3FFAR1PPARAMAPTMEN1 | |
| SCHEMBL1825476 | 0.79 | PPARA (0.64) | AKR1C3FFAR1PPARA | |
| SCHEMBL1823554 | 0.79 | PPARA (0.50) | AKR1C3FFAR1PPARAMAPTMEN1 | |
| SCHEMBL5712857 | 0.78 | FOLH1 (0.42) | FFAR1FOLH1KMT2AL3MBTL1 | |
| SCHEMBL4604742 | 0.77 | KDM4E (0.46) | AKR1C3MAPTMEN1POLBKMT2A | |
| SCHEMBL4604101 | 0.77 | AKR1C3 (0.45) | AKR1C3FFAR1PPARAMAPTMEN1 | |
| SCHEMBL1824139 | 0.77 | PPARA (0.52) | AKR1C3FFAR1PPARA | |
| SCHEMBL1827569 | 0.77 | PPARA (0.52) | AKR1C3PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720825-B1 | ANTHRANILIC ACID DERIVATIVES, METHODS FOR THEIR PREPARATION AND USE AS DHODH INHIBITORS | ACTIVE BIOTECH AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-7074831-B2 | Compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2006-07-11 | — | — | US | disclosed |
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | ACTIVE BIOTECH AB (SE) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187297-A1 | New compounds, methods for their preparation and use thereof | MALT1, TPMT, FUCA1 | AKR1C3 246/4885FFAR1 769/4885FOLH1 3153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.